Logic-Gated Cell Therapies for Unmet Medical Needs
We are developing the Next Generation of Cell Therapies
![](https://immpact-bio.com/wp-content/uploads/2023/04/icons8-team-y2T5hT7pWx4-unsplash-1.png)
Our ImmPACT Bio Platforms
![](https://immpact-bio.com/wp-content/uploads/2023/04/Cells-no-stock-2.png)
Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address antigen escape
![](https://immpact-bio.com/wp-content/uploads/2023/04/Cells-no-stock-2.png)
TGF-β CAR rewires T cell responses to soluble factors to overcome the immune suppressive microenvironment in cancer
![](https://immpact-bio.com/wp-content/uploads/2023/04/Cells-no-stock-2.png)
Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address antigen escape
![](https://immpact-bio.com/wp-content/uploads/2023/04/Cells-no-stock-2.png)
Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address autoimmunity
![](https://immpact-bio.com/wp-content/uploads/2023/04/Cells-no-stock-2.png)
Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address autoimmunity
![](https://immpact-bio.com/wp-content/uploads/2023/04/Cells-no-stock-2.png)
iCAR technology allows specific killing of cancer cells while sparing normal tissue, with potential to treat all solid tumors
![](https://immpact-bio.com/wp-content/uploads/2023/04/Cells-no-stock-2.png)
TGF-β CAR rewires T cell responses to soluble factors to overcome the immune suppressive microenvironment in cancer.
![](https://immpact-bio.com/wp-content/uploads/2023/04/Cells-no-stock-2.png)
iCAR technology allows specific killing of cancer cells while sparing normal tissue, with potential to treat all solid tumors.
Co-founded by and Based on the Research of Pioneering Scientists
![Yvonne Y. Chen, Ph.D](https://immpact-bio.com/wp-content/uploads/2022/11/image-foundation-scientist-01.jpg)
![Antoni Ribas, M.D., Ph.D](https://immpact-bio.com/wp-content/uploads/2022/11/image-foundation-scientist-03.jpg)
![](https://immpact-bio.com/wp-content/uploads/2022/10/image-meet-our-team.jpg)
Meet Our Team
ImmPACT Bio is developing cutting-edge potent and selective CAR T cell technologies to address key biological challenges in treating grievous diseases.
In 2021 ImmPACT Bio merged with Kalthera Therapeutics.
![](https://immpact-bio.com/wp-content/uploads/2023/04/shutterstock_2140344421-1.png)
Get to Know Our Technology
ImmPACT Bio is developing logic-gate-based CAR T platforms that address key challenges for current cell therapies in oncology.
Our technologies are designed to prevent antigen escape, to overcome the immunosuppressive tumor environment, and to cure autoimmune disease.